GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (NAS:NBIX) » Definitions » Shiller PE Ratio

Neurocrine Biosciences (Neurocrine Biosciences) Shiller PE Ratio : 339.98 (As of Apr. 27, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Shiller PE Ratio?

As of today (2024-04-27), Neurocrine Biosciences's current share price is $135.99. Neurocrine Biosciences's E10 for the quarter that ended in Dec. 2023 was $0.40. Neurocrine Biosciences's Shiller PE Ratio for today is 339.98.

The historical rank and industry rank for Neurocrine Biosciences's Shiller PE Ratio or its related term are showing as below:

NBIX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 328.25   Med: 781.77   Max: 10477
Current: 339.98

During the past years, Neurocrine Biosciences's highest Shiller PE Ratio was 10477.00. The lowest was 328.25. And the median was 781.77.

NBIX's Shiller PE Ratio is ranked worse than
98.26% of 517 companies
in the Drug Manufacturers industry
Industry Median: 24.4 vs NBIX: 339.98

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Neurocrine Biosciences's adjusted earnings per share data for the three months ended in Dec. 2023 was $1.440. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.40 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Neurocrine Biosciences Shiller PE Ratio Historical Data

The historical data trend for Neurocrine Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Shiller PE Ratio Chart

Neurocrine Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1,770.24 328.27

Neurocrine Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,770.24 7,811.88 716.47 474.44 328.27

Competitive Comparison of Neurocrine Biosciences's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Shiller PE Ratio falls into.



Neurocrine Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Neurocrine Biosciences's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=135.99/0.4
=339.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Neurocrine Biosciences's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.44/129.4194*129.4194
=1.440

Current CPI (Dec. 2023) = 129.4194.

Neurocrine Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.170 99.695 -0.221
201406 -0.180 100.560 -0.232
201409 -0.210 100.428 -0.271
201412 -0.260 99.070 -0.340
201503 -0.010 99.621 -0.013
201506 -0.280 100.684 -0.360
201509 -0.400 100.392 -0.516
201512 -0.340 99.792 -0.441
201603 -0.220 100.470 -0.283
201606 -0.460 101.688 -0.585
201609 -0.430 101.861 -0.546
201612 -0.510 101.863 -0.648
201703 -0.900 102.862 -1.132
201706 -0.680 103.349 -0.852
201709 -0.130 104.136 -0.162
201712 0.070 104.011 0.087
201803 -0.470 105.290 -0.578
201806 -0.070 106.317 -0.085
201809 0.520 106.507 0.632
201812 0.190 105.998 0.232
201903 -1.120 107.251 -1.352
201906 0.540 108.070 0.647
201909 0.560 108.329 0.669
201912 0.350 108.420 0.418
202003 0.390 108.902 0.463
202006 0.810 108.767 0.964
202009 -0.620 109.815 -0.731
202012 3.580 109.897 4.216
202103 0.330 111.754 0.382
202106 0.430 114.631 0.485
202109 0.230 115.734 0.257
202112 -0.080 117.630 -0.088
202203 0.140 121.301 0.149
202206 -0.180 125.017 -0.186
202209 0.690 125.227 0.713
202212 0.880 125.222 0.909
202303 -0.790 127.348 -0.803
202306 0.950 128.729 0.955
202309 0.820 129.860 0.817
202312 1.440 129.419 1.440

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Neurocrine Biosciences  (NAS:NBIX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Neurocrine Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences (Neurocrine Biosciences) Business Description

Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Executives
Kevin Charles Gorman officer: Sr VP, Business Development 12790 EL CAMINO REAL, SAN DIEGO CA 92130
William H Rastetter director 9885 TOWNE CENTRE DR., SAN DIEGO CA 92121
Kyle Gano officer: Chief Business Dev Officer NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Eiry Roberts officer: Chief Medical Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Julie Cooke officer: Chief Human Resources Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Gary A Lyons director, officer: President and CEO 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Darin Lippoldt officer: Chief Legal Officer C/O VOLCANO CORPORATION, 3661 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Jude Onyia officer: Chief Scientific Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
David W. Boyer officer: Chief Corp. Affairs Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Ingrid Delaet officer: Chief Regulatory Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Matt Abernethy officer: Chief Financial Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92121
Eric Benevich officer: Chief Commerical Officer C/O NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Christine A Poon director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Malcolm Lloyd-smith officer: Chief Regulatory Officer 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080